BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hong YP, Li ZD, Prasoon P, Zhang Q. Immunotherapy for hepatocellular carcinoma: From basic research to clinical use. World J Hepatol 2015; 7(7): 980-992 [PMID: 25954480 DOI: 10.4254/wjh.v7.i7.980] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Peng Y, Wu G, Qiu X, Luo Y, Zou Y, Wei X, Li A. Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma. Front Genet 2022;13:916024. [DOI: 10.3389/fgene.2022.916024] [Reference Citation Analysis]
2 Kim JM, Cho SY, Rhu J, Jung M, Her JH, Lim O, Choi GS, Shin EC, Hwang YK, Joh JW. Adjuvant therapy using ex vivo-expanded allogenic natural killer cells in hepatectomy patients with hepatitis B virus related solitary hepatocellular carcinoma: MG4101 study. Ann Hepatobiliary Pancreat Surg 2021;25:206-14. [PMID: 34053923 DOI: 10.14701/ahbps.2021.25.2.206] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Gupta M, Akhtar J, Sarwat M. MicroRNAs: Regulators of immunological reactions in hepatocellular carcinoma. Semin Cell Dev Biol 2021:S1084-9521(21)00134-8. [PMID: 34049801 DOI: 10.1016/j.semcdb.2021.05.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
4 Dong Y, Wong JSL, Sugimura R, Lam KO, Li B, Kwok GGW, Leung R, Chiu JWY, Cheung TT, Yau T. Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. Cancers (Basel) 2021;13:1949. [PMID: 33919570 DOI: 10.3390/cancers13081949] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
5 Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med 2021;15:155-69. [PMID: 33754281 DOI: 10.1007/s11684-021-0848-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
6 Lv D, Pan L, Zhang R, Yang J, Chen H, Wen Y, Huang M, Ma X, Wang Q, Yang X. Essential oil from Euphorbia esula inhibits proliferation and induces apoptosis in HepG2 cells via mitochondrial dysfunction. Braz J Pharm Sci 2020;56. [DOI: 10.1590/s2175-97902019000317542] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Chieochansin T, Thepmalee C, Grainok J, Junking M, Yenchitsomanus PT. Cytolytic Activity of Effector T-lymphocytes Against Hepatocellular Carcinoma is Improved by Dendritic Cells Pulsed with Pooled Tumor Antigens. Sci Rep 2019;9:17668. [PMID: 31776459 DOI: 10.1038/s41598-019-54087-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
8 Liu Y, Li H, Ye N, Luo CJ, Hu YY, Wu H, Gong JP. Non-Cirrhotic Liver is Associated with Poor Prognosis of Hepatocellular Carcinoma: A Literature Review. Med Sci Monit 2019;25:6615-23. [PMID: 31479436 DOI: 10.12659/MSM.915722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
9 Madduru D, Ijaq J, Dhar S, Sarkar S, Poondla N, Das PS, Vasquez S, Suravajhala P. Systems Challenges of Hepatic Carcinomas: A Review. J Clin Exp Hepatol 2019;9:233-44. [PMID: 31024206 DOI: 10.1016/j.jceh.2018.05.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
10 Dai B, Shi X, Ma N, Ma W, Zhang Y, Yang T, Zhang J, He L. HMQ-T-B10 induces human liver cell apoptosis by competitively targeting EphrinB2 and regulating its pathway. J Cell Mol Med 2018;22:5231-43. [PMID: 30589500 DOI: 10.1111/jcmm.13729] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Longo V, Gnoni A, Casadei Gardini A, Pisconti S, Licchetta A, Scartozzi M, Memeo R, Palmieri VO, Aprile G, Santini D, Nardulli P, Silvestris N, Brunetti O. Immunotherapeutic approaches for hepatocellular carcinoma. Oncotarget 2017;8:33897-910. [PMID: 28420805 DOI: 10.18632/oncotarget.15406] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 8.2] [Reference Citation Analysis]
12 Wang S, Wang A, Lin J, Xie Y, Wu L, Huang H, Bian J, Yang X, Wan X, Zhao H, Huang J. Brain metastases from hepatocellular carcinoma: recent advances and future avenues. Oncotarget 2017;8:25814-29. [PMID: 28445959 DOI: 10.18632/oncotarget.15730] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
13 Lee S, Loecher M, Iyer R. Immunomodulation in hepatocellular cancer. J Gastrointest Oncol. 2018;9:208-219. [PMID: 29564186 DOI: 10.21037/jgo.2017.06.08] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
14 Chakraborty J, Hilgenfeldt E, Cabrera R. Immune Regulation in HCC and the Prospect of Immunotherapy. Molecular Pathology Library 2018. [DOI: 10.1007/978-3-319-68082-8_10] [Reference Citation Analysis]
15 Puzzoni M, Silvestris N, Leone F, Giampieri R, Faloppi L, Demurtas L, Dell'Aquila E, Marino D, Brunetti O, Garattini SK, Ongaro E, Astara G, Orgiano L, Aprile G, Santini D, Scartozzi M. The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following? Target Oncol 2016;11:593-603. [PMID: 27184491 DOI: 10.1007/s11523-016-0437-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
16 Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5395-5404 [PMID: 28839440 DOI: 10.3748/wjg.v23.i29.5395] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
17 Giakoustidis AE, Giakoustidis DE. Immunosuppression strategies in liver transplantation patient; patients with hepatocellular carcinoma. Immunotherapy 2017;9:197-206. [PMID: 28128716 DOI: 10.2217/imt-2016-0110] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Chew V, Lai L, Pan L, Lim CJ, Li J, Ong R, Chua C, Leong JY, Lim KH, Toh HC, Lee SY, Chan CY, Goh BKP, Chung A, Chow PKH, Albani S. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci U S A 2017;114:E5900-9. [PMID: 28674001 DOI: 10.1073/pnas.1706559114] [Cited by in Crossref: 123] [Cited by in F6Publishing: 139] [Article Influence: 20.5] [Reference Citation Analysis]
19 Rai V, Abdo J, Alsuwaidan AN, Agrawal S, Sharma P, Agrawal DK. Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma. Mol Cell Biochem 2018;437:13-36. [DOI: 10.1007/s11010-017-3092-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
20 Ma Z, He H, Sun F, Xu Y, Huang X, Ma Y, Zhao H, Wang Y, Wang M, Zhang J. Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo. J Cancer Res Clin Oncol. 2017;143:1929-1940. [PMID: 28536738 DOI: 10.1007/s00432-017-2436-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
21 Yoo SY, Badrinath N, Woo HY, Heo J. Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma. Mediators Inflamm 2017;2017:5198798. [PMID: 28512387 DOI: 10.1155/2017/5198798] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
22 Yu R, Yang B, Chi X, Cai L, Liu C, Yang L, Wang X, He P, Lu X. Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis. Drug Des Devel Ther. 2017;11:851-864. [PMID: 28360510 DOI: 10.2147/dddt.s124399] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
23 Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther. 2017;173:106-117. [PMID: 28174094 DOI: 10.1016/j.pharmthera.2017.02.010] [Cited by in Crossref: 158] [Cited by in F6Publishing: 177] [Article Influence: 26.3] [Reference Citation Analysis]
24 Ding M, Wang Y, Chi J, Wang T, Tang X, Cui D, Qian Q, Zhai B. Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients. PLoS One. 2016;11:e0168798. [PMID: 28006010 DOI: 10.1371/journal.pone.0168798] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
25 Huang Z, Zhang N, Li W, Cao J, Zhang L, Chen Y. Expression of CHODL in hepatocellular carcinoma affects invasion and migration of liver cancer cells. Oncol Lett 2017;13:715-21. [PMID: 28356950 DOI: 10.3892/ol.2016.5466] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
26 Chacko S, Samanta S. "Hepatocellular carcinoma: A life-threatening disease". Biomed Pharmacother. 2016;84:1679-1688. [PMID: 27823920 DOI: 10.1016/j.biopha.2016.10.078] [Cited by in Crossref: 54] [Cited by in F6Publishing: 65] [Article Influence: 7.7] [Reference Citation Analysis]
27 . FEATURES. Asia-Pacific Biotech News 2016;20:12-32. [DOI: 10.1142/s0219030316000252] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Wang L, Yi Y, Yin D, Zhou Z, Fan J, Ye W, Zhao W. Augmented CD3+CD8+ and CD3+CD56− cells in cytokine-induced killer cells cultured with engineered cells for costimulatory enhancement from heavily pretreated patients with solid tumor. Cytotherapy 2016;18:581-9. [DOI: 10.1016/j.jcyt.2015.11.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
29 Leading-Edge ONCOLOGY (Vol. 20, No. 04, Full Issue). Asia-Pacific Biotech News 2016;20:S0219030316001038. [DOI: 10.1142/s0219030316001038] [Reference Citation Analysis]
30 Wang J, Li M, Wang Y, Liu X. Integrating subpathway analysis to identify candidate agents for hepatocellular carcinoma. Onco Targets Ther. 2016;9:1221-1230. [PMID: 27022281 DOI: 10.2147/ott.s97211] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
31 Cabibbo G, Reig M, Gadaleta-caldarola G, Galati G, Lombardi G, Mazza G, Marzi L, Saitta C, Nault J, Sacco R. The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 2. Future Oncology 2016;12:285-8. [DOI: 10.2217/fon.15.324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Liu D, Staveley-O’Carroll KF, Li G. Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma. J Clin Cell Immunol. 2015;6. [PMID: 26877890 DOI: 10.4172/2155-9899.1000376] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
33 Li L, Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 2016;379:191-197. [PMID: 26213370 DOI: 10.1016/j.canlet.2015.07.018] [Cited by in Crossref: 131] [Cited by in F6Publishing: 143] [Article Influence: 16.4] [Reference Citation Analysis]
34 Li Y, Zhao LL, Li Y, Zhao Y, Li LP. Epigallocatechin-3-gallate induces human liver cancer HepG2 cell apoptosis and growth inhibition by suppressing phosphatidylinositol 3 kinase/protein kinase B signaling. Shijie Huaren Xiaohua Zazhi 2015; 23(20): 3188-3194 [DOI: 10.11569/wcjd.v23.i20.3188] [Reference Citation Analysis]